source
- Recon: Merck KGaA to exit CDMO business; Karyopharm to sell itself in bankruptcyWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 7d ago↗ source
- FDA places uniQure’s Huntington’s gene therapy in priority review, targeting May 2027 approvalThe U.S. Food and Drug Administration has accepted uniQure’s filing for its Huntington’s disease gene therapy and placed the product under priority review, a step that could accelerate a decision b…